SAR442949
Phase 1
SanofiSAR442949 is one of 32 therapeutic programs targeting Retinitis Pigmentosa. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
73 competitors in Retinitis Pigmentosa
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Minocin
TTriax
Phase 3
Aquasol a
BBandim Health Project
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Depakote
AbbViePhase 2
Eylea
RegeneronPhase 2
Alphagan
AbbViePhase 2
Lutein
NNational Eye Institute (NEI)
Phase 3
Levodopa-Carbidopa
AbbViePhase 2
N-Acetylcysteine Amide
NNacuity Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for SAR442949. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company